- GW Home
- About GW
- University Life
- News & Events
- Faculty And Staff
Aprepitant to treat hypomagnesemia and skin lesions during chemotherapyTechnology #014-050-weglicki
Questions about this technology? Ask a Technology Manager
- Image Gallery
- William B. Weglicki External Link (www.gwumc.edu)
- Iu Tong Mak External Link (www.gwumc.edu)
- Managed By
- Brian Coblitz Sr. Licensing Associate firstname.lastname@example.org (202) 994-4345
- Patent Protection
Use of nk-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with egfr-blocking drugsUS Patent 9,474,761
Use of NK-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with EGFR-blocking drugsUS Patent 9,687,493
- EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade J Cardiovasc Pharmacol, 2015 Jan;65(1):54-61
Dietary administration of anti-vomiting drug Aprepitant to treat hypomagnesemia resulting from chemotherapy represents a new use for this commercial drug. Progressive hypomagnesemia, characterized by pronounced decrease (22-28%) of blood magnesium levels, occurs after prolonged chemotherapy with EGFR pathway blockers, such as Erlotinib or Cetuximab. Magnesium depletion leads to systemic oxidative distress, inflammation (including skin lesions) and eventual cardiac dysfunction. Other biochemical abnormalities, caused by magnesium depletion, include impaired calcium metabolism as manifested by hypocalcemia, hypoparathyroidism, and parathyroid hormone resistance.
Erlotinib, a tyrosine kinase inhibitor, causes elevation in circulating Substance P (SP). GW researchers established that elevated SP correlates with hypomagnesemia and then predicted that a SP blocker, like Aprepitant, could provide a treatment. The therapeutic approach is a first ever in hypomagnesemia, which is traditionally managed by replenishing magnesium levels with magnesium salts either orally or intravenously. In contrast, the inventors address the underlying molecular cause of magnesium depletion, i.e. elevated SP levels, and treat that with an oral drug already used for humans.
Preclinical validation data in animal models indicated that Aprepitant treatment completely prevented the development of cardiac systolic and diastolic dysfunction. Co-administration of Aprepitant with Erlotinib during chemotherapy could prevent systemic stress and cardiac dysfuction. Additionally, researchers observed an incredible impact on prevention of skin lesions with Aprepitant and envision applying Aprepitant topically as needed for this indication.
• Treat hypomagnesemia
• Use of NK-1 Receptor blockers to treat complications of EGFR blocking drugs and prolong chemotherapy adherance
• Aprepitant (Emend) is already in clinical use
• Targets the underlying cause of hypomagnesemia and skin lesions